Dementia professor on new Biogen approval: The first small step towards new developments

Biogen's Aduhelm is the first new Alzheimer's drug approved for nearly twenty years, and this pleases Professor of Clinical Neurology Gunhild Waldemar.

Professor of Clinical Neurology at Rigshospitalet, University of Copenhagen, Gunhild Waldemar | Photo: Tomas Bertelsen / Nationalt Videnscenter for Demens / PR

The official approval of a drug rarely resonates outside the circle of medical professionals and patients who stand to benefit from the new treatment. However, US biotech company Biogen has garnered attention due to its new drug, which was approved on Monday.

Its treatment aducanumab, which will now be known as Aduhelm, is the first new approved treatment for Alzheimer's disease for almost twenty years.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs